Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Two Days, Two Deals: AbbVie To Partner (Again) With Galapagos In Cystic Fibrosis

This article was originally published in The Pink Sheet Daily

Executive Summary

AbbVie’s busy week continued when it unveiled a collaboration with Galapagos in cystic fibrosis Sept. 24, a day after it announced an inflammatory disease tie-up with Ablynx. AbbVie and Galapagos already are partnered under a 2012 deal in rheumatoid arthritis and Crohn’s disease.

You may also be interested in...



Start-Up Quarterly Statistics, Q3 2013

Start-up fundraising for Q3 2013 totaled $559.4 million, down from last quarter’s big rally ($907.2 million) but still up from the sluggish first quarter ($398.7 million). More than half of that money went to biopharma companies, a group which also received investments through alliances with equity provisions.

Cystic Fibrosis Market Snapshot: Disease-Modifying Drugs Elusive 24 Years After Discovery Of Root Cause

The discovery in 1989 of the underlying genetics causing cystic fibrosis was expected to spur broad development of disease-modifying therapies. As of 2013, however, only one such drug is on the market, for a small subset of CF patients, and a few other candidates are in clinical development.

Abbott Pays Top Dollar For Galapagos’ Autoimmune Drug

As its pharma division separates from its diversified medical products unit, Abbott obtains another drug that could succeed Humira in rheumatoid arthritis and related indications.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM007836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel